Merck advances Alzheimer's treatment into Phase 3 clinicals

Dec. 10, 2013 1:04 PM ETMerck & Co., Inc. (MRK)MRK, LGNDBy: Colin Lokey, SA News Editor
  • After passing an interim safety analysis, Merck's (MRK -0.6%) investigational BACE inhibitor MK-8931 will move into Phase 3 testing for the treatment of Alzheimer's.
  • MRK will also begin a Phase 3 study in early-stage prodromal patients.
  • This marks the first time a drug in this class has made it to Phase 3 trials, the company notes. A JPMorgan analyst cited by Reuters says the drug could see sales of $5B if it is eventually approved.
  • The news is of interest to Ligand Pharmaceuticals (LGND +0.7%) which would receive royalties on the product.
  • Here's Cantor's Irina Rivkind commenting: "We view this program as high risk given the failure rate in prior Alzheimer's compounds but do think that program progression removes an overhang from LGND."

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.